Wei‐Min Tong
- Oncology top 2%
- Cancer-related Molecular Pathways 13
- PARP inhibition in cancer therapy 13
- Pancreatic and Hepatic Oncology Research 5
- Cancer Research top 2%
- Cancer-related molecular mechanisms research 11
- Molecular Biology top 2%
- DNA Repair Mechanisms 21
- RNA modifications and cancer 17
- Epigenetics and DNA Methylation 11
- Cancer-related gene regulation 10
- Aging top 5%
- Developmental Neuroscience top 5%
- Co-authors
- Zhao‐Qi WangPeter M. LansdorpM. Prakash HandeUlrich CortesStephen P. JacksonFabrizio d’Adda di FagagnaD. GalendoPhilippe Bertolino
- Journals
- International Journal of Cancer (5 papers)Oncogene (4 papers)Molecular and Cellular Biology (3 papers)
- Partner nations
- ChinaFranceUnited States
In The Last Decade
Wei‐Min Tong
74 papers receiving 3.8k citations
Peers
Comparison fields: 5 of 107
- Oncology 1.4k
- Cancer Research 730
- Molecular Biology 2.7k
- Aging 56
- Developmental Neuroscience 85
Countries citing papers authored by Wei‐Min Tong
This map shows the geographic impact of Wei‐Min Tong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐Min Tong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐Min Tong more than expected).
Fields of papers citing papers by Wei‐Min Tong
This network shows the impact of papers produced by Wei‐Min Tong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐Min Tong. The network helps show where Wei‐Min Tong may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Wei‐Min Tong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 29 | |
| 4 | 2023 | 6 | |
| 5 | 2022 | 29 | |
| 6 | 2022 | 43 | |
| 7 | 2021 | 13 | |
| 8 | 2020 | 1 | |
| 9 | 2020 | 117 | |
| 10 | 2017 | 63 | |
| 11 | 2014 | 20 | |
| 12 | 2013 | 10 | |
| 13 | 2013 | 14 | |
| 14 | 2012 | 21 | |
| 15 | 2006 | 105 | |
| 16 | 2003 | 191 | |
| 17 | 2001 | 141 | |
| 18 | 1998 | 27 | |
| 19 | 1998 | 2 | |
| 20 | 1995 | 23 |
About Wei‐Min Tong
Wei‐Min Tong is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 75 papers that have together received 3.9k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (21 papers), RNA modifications and cancer (17 papers), Cancer-related Molecular Pathways (13 papers), PARP inhibition in cancer therapy (13 papers), Cancer-related molecular mechanisms research (11 papers), Epigenetics and DNA Methylation (11 papers), Cancer-related gene regulation (10 papers) and Pancreatic and Hepatic Oncology Research (5 papers). The work is most often cited by research in Oncology (1.4k citations), Cancer Research (730 citations) and Molecular Biology (2.7k citations). Wei‐Min Tong has collaborated with scholars based in China, France and United States. Frequent co-authors include Zhao‐Qi Wang, Peter M. Lansdorp, M. Prakash Hande, Ulrich Cortes, Stephen P. Jackson, Fabrizio d’Adda di Fagagna, D. Galendo, Philippe Bertolino, Chang Zhang and Yamei Niu. Their work appears in journals such as International Journal of Cancer, Oncogene, Molecular and Cellular Biology, Clinical Epigenetics and Cell Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.